Clinical Trials Directory

Trials / Unknown

UnknownNCT05850611

The Effect of Combination Therapy of Oral MB and PRP-FG in Patients With Non-healing Diabetic Foot Ulcer

The Effect of Combination Therapy of Oral Methylene Blue and Platelet-rich Plasma-fibrin Glue in Patients With Non-healing Diabetic Foot Ulcer: a Pilot Study

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Mashhad University of Medical Sciences · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the chance of non-healing diabetic foot ulcers repair by improving the condition of lack of oxygen or hypoxia in the wound area caused by diabetes using methylene blue along with the use of platelet-rich plasma-fibrin glue as an effective treatment for wound healing.

Detailed description

The current study assesses the effects of methylene blue along with the use of platelet-rich plasma-fibrin glue on wound healing in patients with nonhealing diabetic foot ulcers (non-healing DFU). This randomized controlled trial is performed on 20 patients with non-healing DFU. Patients were treated with PRP-FG dressing plus 200 ml of oral methylene blue dissolved in milk(intervention group) or PRP-FG dressing plus placebo (200 ml of milk) (control group) for 4 weeks.

Conditions

Interventions

TypeNameDescription
DRUGMethylene BlueThe first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks.
OTHERMilk (control)Group B will receive 200 ml of milk for 4 weeks.
DRUGMethylene Blue and Platelet-Rich Plasma-Fibrin GlueGroup C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue.
OTHERMilk and Platelet-Rich Plasma-Fibrin Glue (control)Group D will be treated only with fibrin glue and 200 ml of milk for 4 weeks.

Timeline

Start date
2023-04-30
Primary completion
2023-08-21
Completion
2024-09-21
First posted
2023-05-09
Last updated
2023-10-04

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT05850611. Inclusion in this directory is not an endorsement.